{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:53:52Z","timestamp":1790909632716,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T00:00:00Z","timestamp":1423526400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s12149-015-0957-7","type":"journal-article","created":{"date-parts":[[2015,2,9]],"date-time":"2015-02-09T08:13:37Z","timestamp":1423469617000},"page":"391-399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["An exploratory efficacy study of the amyloid imaging agent [18F]flutemetamol in Japanese Subjects"],"prefix":"10.1007","volume":"29","author":[{"given":"Michio","family":"Senda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"McParland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Heurling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,10]]},"reference":[{"key":"957_CR1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0447.2010.01587.x","volume":"122","author":"A Sekita","year":"2010","unstructured":"Sekita A, Ninomiya T, Tanizaki Y, Doi Y, Hata J, Yonemoto K, et al. Trends in prevalence of Alzheimer\u2019s disease and vascular dementia in a Japanese community: the Hisayama Study. Acta Psychiatr Scand. 2010;122:319\u201325.","journal-title":"Acta Psychiatr Scand"},{"key":"957_CR2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","volume":"9","author":"M Prince","year":"2013","unstructured":"Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metanalysis. Alzheimers Dement. 2013;9:63\u201375.","journal-title":"Alzheimers Dement"},{"key":"957_CR3","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV. 4th Edn, 1994."},{"key":"957_CR4","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","volume":"50","author":"N Nelissen","year":"2009","unstructured":"Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase I study of the Pittsburgh compound B derivative 18F-Flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50:1251\u20139.","journal-title":"J Nucl Med"},{"key":"957_CR5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2967\/jnumed.108.060756","volume":"50","author":"M Koole","year":"2009","unstructured":"Koole M, Lewis DM, Buckley C, Nelissen N, Vandenbulcke M, Brooks DJ, et al. Whole-body distribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med. 2009;50:818\u201322.","journal-title":"J Nucl Med"},{"key":"957_CR6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ana.22068","volume":"68","author":"R Vandenberghe","year":"2010","unstructured":"Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319\u201329.","journal-title":"Ann Neurol"},{"key":"957_CR7","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000335381","volume":"10","author":"L Thurfjell","year":"2012","unstructured":"Thurfjell L, L\u00f6tj\u00f6nen J, Lundqvist R, Koikkalainen J, Soininen H, Waldemar G, et al. Combination of biomarkers: PET [18F]flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neurodegener Dis. 2012;10:246\u20139.","journal-title":"Neurodegener Dis"},{"key":"957_CR8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000355256","volume":"13","author":"JO Rinne","year":"2014","unstructured":"Rinne JO, Frantzen J, Leinonen V, Lonnrot K, Laakso A, Virtanen KA, et al. Prospective Flutemetamol Positron Emission Tomography and Histopathology in Normal Pressure Hydrocephalus. Neurodegener Dis. 2014;13:237\u201345.","journal-title":"Neurodegener Dis"},{"key":"957_CR9","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1001\/archneurol.2011.153","volume":"68","author":"DA Wolk","year":"2011","unstructured":"Wolk DA, Grachev ID, Buckley C, Kazi H, Grady MS, Trojanowski JQ, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 2011;68:1398\u2013403.","journal-title":"Arch Neurol"},{"key":"957_CR10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00259-013-2564-y","volume":"41","author":"S Hatashita","year":"2014","unstructured":"Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2014;41:290\u2013300.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"957_CR11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00004728-199701000-00027","volume":"21","author":"J Andersson","year":"1997","unstructured":"Andersson J, Thurfjell L. Implementation and validation of a fully automatic system for intra- and interindividual registration of PET brain scans. J Comput Assist Tomogr. 1997;21:136\u201344.","journal-title":"J Comput Assist Tomogr"},{"key":"957_CR12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/jcbfm.1991.103","volume":"11","author":"AA Lammertsma","year":"1991","unstructured":"Lammertsma AA, Bench CJ, Price GW, Cremer JE, Luthra SK, Turton D, et al. Measurement of cerebral monoamine oxidase B activity using L-[11C]deprenyl and dynamic positron emission tomography. J Cereb Blood Flow Metab. 1991;11:545\u201356.","journal-title":"J Cereb Blood Flow Metab"},{"key":"957_CR13","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/jcbfm.1990.127","volume":"10","author":"J Logan","year":"1990","unstructured":"Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N\u201311C\u2013methyl]\u2013(\u2013)cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740\u20137.","journal-title":"J Cereb Blood Flow Metab"},{"key":"957_CR14","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","volume":"16","author":"J Logan","year":"1996","unstructured":"Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834\u201340.","journal-title":"J Cereb Blood Flow Metab"},{"key":"957_CR15","first-page":"1959","volume":"46","author":"BJ Lopresti","year":"2005","unstructured":"Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification if Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959\u201372.","journal-title":"J Nucl Med"},{"key":"957_CR16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00259-011-2021-8","volume":"39","author":"V Camus","year":"2012","unstructured":"Camus V, Payoux P, Barr\u00e9 L, Desgranges B, Voisin T, Tauber C, et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging. 2012;39:621\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"957_CR17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2967\/jnumed.112.107185","volume":"54","author":"GA Becker","year":"2013","unstructured":"Becker GA, Ichise M, Barthel H, Luthardt J, Patt M, Seese A, et al. PET quantification of 18F-florbetaben binding to \u03b2-amyloid deposits in human brains. J Nucl Med. 2013;54:723\u201331.","journal-title":"J Nucl Med"},{"key":"957_CR18","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1212\/01.wnl.0000240117.55680.0a","volume":"67","author":"NM Kemppainen","year":"2006","unstructured":"Kemppainen NM, Aalto S, Wilson IA, N\u00e5gren K, Helin S, Br\u00fcck A, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology. 2006;67:1575\u201380.","journal-title":"Neurology"},{"key":"957_CR19","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.2967\/jnumed.112.115006","volume":"54","author":"R Lundqvist","year":"2013","unstructured":"Lundqvist R, Lilja J, Thomas BA, L\u00f6tj\u00f6nen J, Villemagne VL, Rowe CC, et al. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. J Nucl Med. 2013;54:1472\u20138.","journal-title":"J Nucl Med"},{"key":"957_CR20","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2967\/jnumed.114.142109","volume":"54","author":"L Thurfjell","year":"2014","unstructured":"Thurfjell L, Lilja J, Lundqvist R, Buckley C, Smith A, Vandenberghe R, et al. Automated quantification of 18F-flutemetamol PET activity for categirizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med. 2014;54:1623\u20138.","journal-title":"J Nucl Med"},{"key":"957_CR21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh compound-B. Annal Neurol. 2004;55:306\u201319.","journal-title":"Annal Neurol"},{"key":"957_CR22","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","volume":"67","author":"MA Mintun","year":"2006","unstructured":"Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in non-demented population: a potential antecedent marker of Alzheimers disease. Neurology. 2006;67:446\u201352.","journal-title":"Neurology"},{"key":"957_CR23","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1093\/brain\/awm238","volume":"130","author":"KE Pike","year":"2007","unstructured":"Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer\u2019s disease. Brain. 2007;130:2837\u201344.","journal-title":"Brain"},{"key":"957_CR24","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","volume":"65","author":"HJ Aizenstein","year":"2008","unstructured":"Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arc Neurol. 2008;65:1509\u201317.","journal-title":"Arc Neurol"},{"key":"957_CR25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/brain\/awm336","volume":"131","author":"CR Jack Jr","year":"2008","unstructured":"Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer\u2019s disease and amnestic mild cognitive impairment. Brain. 2008;131:665\u201380.","journal-title":"Brain"},{"key":"957_CR26","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awn320","volume":"132","author":"EC Mormino","year":"2009","unstructured":"Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132:1310\u201323.","journal-title":"Brain"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-015-0957-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-015-0957-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-015-0957-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T09:53:41Z","timestamp":1691142821000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-015-0957-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["957"],"URL":"https:\/\/doi.org\/10.1007\/s12149-015-0957-7","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,10]]}}}